Clarify Health

Overview

Clarify Health is a healthcare analytics company whose Clarify Atlas platform supports payer, provider, and life-sciences use cases. For Rx Almanac, the manufacturer-relevant lane is life-sciences analytics: real-world data, patient journey analytics, clinical development support, commercial targeting, market access reporting, health equity analysis, and RWE studies for pharmaceutical and biotech organizations.

Clarify should be evaluated as an analytics and evidence vendor, not as a patient-services operator. Its manufacturer-relevant fit is life-sciences analytics, global-biopharma and top-10-pharma use cases, RWE applications for pharma and biotech customers, and Pfizer-linked RWE content.

Real-World Evidence Capability Model

The framework below standardizes how Rx Almanac evaluates real-world-evidence capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Clarify Health is evaluated as an analytics and evidence vendor, not as a patient-services operator.

Capability	Buyer should compare	Clarify Health readout
Data assets and linkage coverage	Claims, EHR, registry, lab, mortality, genomic, provider, and patient-level linkage breadth.	Core. Clarify Atlas is positioned as the data and analytics layer for patient journey and life-sciences insight. Validate in RFP. Buyers should request study protocols and sample outputs. Validate in RFP. Clarify informs decisions; it does not execute patient services.
Study design and causal inference	Protocol development, statistical methods, bias control, synthetic/external controls, and reproducibility.	Core. Public materials include RWE and health-disparities use cases. Adjacent strength. Clarify can support trial-site and recruitment analytics when the use case is evidence-led.
Regulatory, HTA, and payer evidence packages	FDA, EMA, NICE/HTA, payer value dossiers, label expansion, and post-market evidence use cases.	Not the main buying reason for Clarify Health; validate only if the SOW includes regulatory, hta, and payer evidence packages.
Oncology, rare disease, and specialty depth	Fit for small populations, biomarkers, longitudinal oncology records, rare-disease cohorts, and specialty-drug endpoints.	Not the main buying reason for Clarify Health; validate only if the SOW includes oncology, rare disease, and specialty depth.
Analytics platform and self-service workflow	User-facing software, cohort builders, query tools, dashboards, and analyst service model.	Adjacent strength. Clarify supports commercial and market-access analytics alongside RWE.
Privacy, governance, and refresh cadence	HIPAA controls, de-identification, data rights, governance, update frequency, and auditability.	Core diligence item. Confirm refresh timing and data-use rights.

Buyer Fit

• Best shortlist motion: Include Clarify when RWE, patient-journey analytics, commercial targeting, or health-equity evidence is the buying problem.
• Best-fit buyers: HEOR, medical affairs, market access, commercial analytics, brand, biotech, payer/provider strategy, and healthcare-technology teams that need patient-journey insight.
• Less ideal fit: Hub operations, reimbursement casework, copay, specialty pharmacy, or fulfillment workflows.
• Commercial fit: Scope should define data cuts, methodology, deliverables, export rights, refresh cadence, and advisory support.
• Therapeutic fit: Therapeutic-area agnostic, with public examples touching oncology, rare disease, health equity, and commercial launch analytics.
• Validate before award: Confirm that the specific therapy area, data depth, and intended stakeholder use case are proven in comparable pharma work.

Differentiators

• Patient journey analytics: Clarify’s strongest public lane is longitudinal journey visibility for life-sciences and payer/provider use cases.
• RWE plus commercial use: The platform bridges HEOR, market access, targeting, and care-gap analytics.
• Health-equity signal: Public RWE materials include health-disparities and SDOH-oriented analytics.
• Pfizer-linked public example: Clarify has public content tied to Pfizer RWE work in rare-disease diagnostic testing patterns.
• Atlas platform layer: Clarify Atlas is the data and software layer buyers should diligence for patient-journey continuity, cohort logic, claims and clinical depth, and dashboard exportability.

RFP Questions

• Which datasets, refresh cadence, and patient-linkage methods are included in the proposed scope?
• How are cohorts, endpoints, SDOH variables, and care-gap definitions validated?
• What study outputs are suitable for HEOR, medical, payer, or commercial use?
• Which exports, dashboards, and data-use rights are included for manufacturer teams?
• How are tokenization, privacy controls, methodology documentation, and reproducibility handled across medical, commercial, market-access, and HEOR teams?
• What named references can Clarify provide by therapy area, analytics use case, data cut, and buyer stakeholder?
• How does Clarify separate analytics/advisory work from operational patient-services responsibilities?

Recent Activity

• 2026-05 - Current Clarify materials lean more heavily toward Meridian, provider outcomes, and payer/provider analytics; manufacturers should confirm the active life-sciences scope before award.

• 2022: Public funding summaries identified Clarify’s $150 million Series D financing.

• 2021: Clarify launched RWE applications focused on health disparities for life-sciences organizations.

• 2020: LexisNexis Risk Solutions and Clarify announced work on SDOH and clinical-data predictive capability.

See Also

• Komodo Health — Pharma data and RWE analytics platform
• Turquoise Health — Price transparency and contract intelligence platform
• IQVIA — Global pharma data, analytics, CRO, and commercial technology platform
• ConcertAI — Oncology RWE and life-sciences evidence platform